| The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. | |
| | |
MedLine Citation:
|
PMID: 23300029 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
There are many active drugs to treat metastatic renal cell carcinoma (mRCC) patients who progress through their first-line vascular endothelial growth factor (VEGF) inhibitor. Many clinicians choose a second-line VEGF inhibitor based on the type of response to first-line VEGF inhibitor, without data supporting this practice. This study was conducted to determine the association of response to second-line VEGF inhibitor with response to first-line VEGF inhibitor. All mRCC patients in participating centers of the International mRCC Database Consortium who were treated from January 2004 through June 2011 with a second-line VEGF inhibitor after failure of a different first-line VEGF inhibitor were retrospectively identified. The primary outcome is objective response rate (ORR) and the secondary outcome is progression-free survival (PFS) in each line of therapy. Of 1,602 total database patients, 464 patients received a first- and second-line VEGF inhibitor. The ORR to first-line therapy was 22 %, and the ORR to second-line therapy was 11 %. The ORR to second-line therapy was not different among patients achieving partial response versus stable disease versus progressive disease to first-line therapy (14 % vs. 10 % vs. 11 %, respectively; chi-squared trend test p = 0.17). The median PFS on first-line VEGF-targeted therapy was 7.5 months (95 % CI, 6.6-8.1), and the median PFS on second-line VEGF inhibitor was 3.9 months (95 % CI, 3.6-4.5). There was no correlation between first-line and second-line PFS (Pearson correlation coefficient 0.025; p = 0.59). The clinical response to a second-line VEGF inhibitor is not dependent on response to the first-line VEGF-inhibitor. Further studies are needed to define clinical parameters that predict response to second-line therapy to optimize the sequence of VEGF-targeted therapy in metastatic RCC patients. |
| | |
Authors:
|
Mhd Y Al-Marrawi; Brian I Rini; Lauren C Harshman; Georg Bjarnason; Lori Wood; Ulka Vaishampayan; Mary Mackenzie; Jennifer J Knox; Neeraj Agarwal; Hulayel Al-Harbi; Christian Kollmannsberger; Min-Han Tan; Sun Young Rha; Frede N Donskov; Scott North; Toni K Choueiri; Daniel Y Heng; |
Related Documents
:
|
16184589 - Hypereosinophilic syndrome: an update. 23286739 - Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of tran... 16551519 - Optimizing chemotherapy and targeted agent combinations in nsclc. 23357879 - Wild-type kras and braf could predict response to cetuximab in chinese colorectal cance... 23404099 - In vivo efficacy of melanoma internal radionuclide therapy with a (131) i-labelled mela... 20370649 - Bench to bedside targeting of flt3 in acute leukemia. 7608719 - Prospective evaluation of a prognostic index for intrinsic supratentorial tumours. 21108439 - Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in ch... 22500049 - Advancing the status of mpn pathogenesis. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: Targeted oncology Volume: - ISSN: 1776-260X ISO Abbreviation: Target Oncol Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101270595 Medline TA: Target Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: EGFR-directed monoclonal antibodies in non-small cell lung cancer.
Next Document: The design and analysis of parallel experiments to produce structurally identifiable models.